Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C

Showing 301 to 310 of 365 resources

  • Evaluation of the pilot provision of single use plastic water ampoules to people who inject drugs in Glasgow
    Greater Glasgow and Clyde (GG&C) has an estimated injecting population of 8862. There are 74 Injecting Equipment Provision (IEP) outlets across the area to meet the paraphernalia needs of this population. Since 2009 GG&C has provided a comprehensive package of paraphernalia, including needle choice, spoons, filters, citric acid and swabs. However, until the start of this pilot, water for injecting (WFI) was not available from any of the 62 pharmacy outlets. In fact prior to the pilot only 3 outlets provided WFI and this was in a glass ampoule form.
    Scotland Sep 2012 Case study, Reports & Research PDF
  • Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965
    Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7–3.9 million persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical monitoring) and treatment. CDC estimates that although persons born during 1945–1965 comprise an estimated 27% of the population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associated
    Rest of World 17 Aug 2012 Reports & Research PDF
  • National survey of hepatitis C services in prisons in England, July 2012
    This is the first dedicated survey of hepatitis C services in prisons in England. The survey aim was to collect basic information on what type of services are provided in prisons for the diagnosis, treatment and follow-up of prisoners infected by hepatitis C.
    England Jul 2012 Reports & Research PDF
  • Hepatitis C in the UK - 2012 Report
    The most recent national estimates in 2012 suggested that around 216,000 individuals were chronically infected with hepatitis C (HCV) in the UK. Both hospital admissions and deaths from HCV-related end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) are continuing to rise. In England, statistical modelling predicts that 15,840 individuals will be living with HCV-related cirrhosis or HCC in England in 2020 if left untreated.
    UK Jul 2012 Reports & Research PDF
  • NHS Liver Care E-seminar: Making Every Contact Count
    This document provides a summary of the key points made by Professor Martin Lombard, National Clinical Director for Liver Disease, during an NHS presentation he gave. He provides an overview of the high prevalence of liver disease in England and discusses the reasons for this high prevalence and what measures could be taken to lower the number of cases of liver disease. The document also provides a link to listen to the e-seminar.
    England 13 Jun 2012 Other MS Word
  • Hepatitis C Prevalence and Incidence among Scottish Prisoners and Staff Views of its Management: Final Report
    This report aims to generate reliable data on prevalence and incidence of hepatitis C to inform the Scottish Prison Service and the NHS to develop effective needs-led interventions for hepatitis C (HCV) infected prisoners, and to enable an informed assessment of the effectiveness of measures to prevent the spread of blood borne viruses, especially hepatitis C, within the prison setting, as outlined in the Hepatitis C (Phase (II)) Action Plan for Scotland (2008).
    England, Scotland May 2012 Reports & Research PDF
  • Health and Social Care Act 2012
    The Health and Social Care Act 2012 aims to safeguard the future of the NHS by modernising it to better tackle the problems of today and avoid crisis tomorrow. It sets out a plan to put clinicians at the centre of commissioning, freeing up providers to innovate, empowering patients and giving a new focus to public health.
    England 27 Mar 2012 Other PDF
  • Deaths from liver disease: Implications for end of life care in England - March 2012
    This report presents key facts about deaths from liver disease in England. It highlights differences in place and cause of death by age, sex and deprivation. It is aimed at commissioners and providers of end of life care, clinicians caring for patients with liver disease, and others concerned with providing quality end of life care for this patient group, including patients themselves and their carers. The report gives the first summary of high level statistics on deaths from liver disease on which future discussions can be built.
    England Mar 2012 Reports & Research PDF
  • Guidance on testing for hepatitis B and C (with reference to HIV) Developed by Yorkshire and the Humber Hepatitis B and C Steering Group
    Individuals with chronic hepatitis (B and C) can be treated, which reduces the likelihood of chronic illness and premature death. Recognition of infection and treatment may also reduce the spread of infection. In 2010 across Yorkshire and the Humber there were 427 cases of hepatitis B (of which 39 were acute) and 980 newly identified hepatitis C infections reported through NHS/HPA laboratory testing, however HPA estimates calculate that there are over 20,000 people actually infected with hepatitis C in the region.
    Yorkshire and the Humber Mar 2012 Tools & Templates, Strategy & Planning PDF
  • Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
    This paper reports on the results of a 2011 EASL meeting and subsequent dialogue with patient groups and relevant experts in Europe. It summarises the current knowledge of HCV infection and the brain; prevalence, course, and neurobiology of IFN-a associated psychiatric side effects; possible risk factors for IFN-a associated depression and suicide attempts; psychiatric management of HCV infected patients before and during antiviral treatment; prevention of IFN- a associated psychiatric side effects; and psychiatric aspects of the new antivirals.
    UK, Rest of World 2012 Reports & Research PDF